GalapagosGLPG
About: Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Employees: 704
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
144% more call options, than puts
Call options by funds: $28.7M | Put options by funds: $11.8M
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
14% more capital invested
Capital invested by funds: $780M [Q1] → $887M (+$107M) [Q2]
1% more funds holding
Funds holding: 82 [Q1] → 83 (+1) [Q2]
0.93% more ownership
Funds ownership: 47.15% [Q1] → 48.07% (+0.93%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
Research analyst outlook
We haven’t received any recent analyst ratings for GLPG.
Financial journalist opinion
